13 September 2016 - Mylan, lambasted for raising prices, ranks No. 2 in U.S. pharmaceutical industry in executive compensation.

The drug maker buffeted by the furor over hefty price increases on its lifesaving EpiPen had the second-highest executive compensation among all U.S. drug and biotech firms over the past five years, paying its top five managers a total of nearly $300 million, according to a Wall Street Journal analysis.

The big pay packages are unusual because of Mylan's relatively small size in the U.S. drug industry, where it is No. 11 by revenue and No. 16 by market capitalization.

Companies generally set their executive pay targets relative to peers in their own industry, with larger companies typically offering more generous pay than smaller ones. Pay also varies somewhat with corporate performance.

Read Wall Street Journal article